The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: A randomized, placebo-controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 3, 2001, Pages 1140-1143

  Perera, Mahesh ^a,b   Sattar, Naveed ^b,c   Petrie, John R ^b   Hillier, Chris ^b   Small, Michael ^b   Connell, John M C ^b   Lowe, Gordon D O ^b   Lumsden, Mary Ann ^b  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; NORETHISTERONE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EPITHELIUM CELL; FEMALE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

EID: 0035048787     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.3.7297     Document Type: Article

References (26)

1. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
2. Diabetes mellitus and cardiovascular disease in women
3. Postmenopausal oestrogen and progestogen use and the risk of cardiovascular disease
4. Hormone replacement therapy and cardiovascular risk in post-menopausal women with NIDDM
5. Mortality and hormone-related exposures in women with diabetes
6. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes
7. Is hormone replacement therapy prescribed for postmenopausal diabetic women?
8. Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus
9. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
10. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus
11. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
12. Multiple beneficial effects of estrogen on lipoprotein
13. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM
14. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
15. Triglyceride-rich lipoproteins: Are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?
16. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
17. Low serum paraoxonase: A risk factor for atherosclerotic disease?
18. Effects of deprivation and effects of percutaneous 17β oestradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes
19. The effects of transdermal oestradiol and oral progestogens on haemostasis variables
20. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
21. Haemostatic function and cardiovascular death: Early results of a prospective study
22. Postprandial lipaemia and haemostatic factors
23. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
24. IL-6 expression by oral fibroblasts is regulated by androgens
25. Progesterone and maintenance of pregnancy: Is progesterone nature's immunosuppressant?
26. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study